利拉鲁肽治疗后2型糖尿病合并冠心病患者肠道菌群变化及其与糖、脂代谢指标相关性

doi:10.12092/j.issn.1009-2501.2025.08.009

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (8): 1084-1091.doi: 10.12092/j.issn.1009-2501.2025.08.009

利拉鲁肽治疗后2型糖尿病合并冠心病患者肠道菌群变化及其与糖、脂代谢指标相关性

邢英, 郑嵘炅, 姜春晖, 玛依拉·卡哈尔, 木胡牙提·乌拉斯汉

新疆医科大学第一附属医院综合内四科,乌鲁木齐 830000,新疆

收稿日期:2024-08-01 修回日期:2024-10-21 发布日期:2025-08-12
通讯作者: 木胡牙提·乌拉斯汉,男,博士,教授,博导,主任医师,从事心血管基础与临床研究。E-mail： muhuyati@163.com
作者简介:邢英,女,博士研究生,副主任医师,从事糖尿病基础和临床相关研究。E-mail： 86143807@qq.com
基金资助:
2025年度自治区卫生健康保健科研专项项目（BL202518）

Changes of intestinal flora in patients with type 2 diabetes mellitus complicated with coronary heart disease after liraglutide treatment and its correlation with glucose and lipid metabolism indexes

XING Ying, ZHENG Rongjiong, JIANG Chunhui, Mayila·kahaer, Muhuyati·wulasihan

Department of Endocrinology, Xinjiang Medical University First Affiliated Hospital, Urumqi 830000, Xinjiang, China

Received:2024-08-01 Revised:2024-10-21 Published:2025-08-12

摘要/Abstract

摘要： 目的：探究利拉鲁肽治疗后2型糖尿病合并冠心病患者肠道菌群变化特征及其与糖、脂代谢指标相关性。方法：选取2019年6月至2022年3月新疆医科大学第一附属医院收治的2型糖尿病合并冠心病患者26例,比较利拉鲁肽治疗前后患者糖、脂代谢指标以及肠道菌群（高通量测序技术）的变化,并分析糖、脂代谢指标与肠道菌群的相关性。结果：与治疗前相比,患者的糖代谢指标和脂代谢指标均呈显著降低的变化趋势（P<0.01）;利拉鲁肽对肠道菌群多样性无显著影响（P>0.05）,但能够显著改变肠道菌群组成（P<0.05）;在毛螺菌科等有益菌显著增加的同时,显著降低埃希氏杆菌属等致病菌丰度（P<0.05）,促进短链脂肪酸生成及机体代谢。结论：利拉鲁肽能够影响2型糖尿病合并冠心病患者肠道菌群组成进而参与调节糖、脂代谢过程。

关键词: 2型糖尿病, 冠心病, 肠道菌群, 利拉鲁肽

Abstract: AIM: To explore the changes of intestinal flora in patients with type 2 diabetes mellitus complicated with coronary heart disease after liraglutide treatment and its correlation with glucose and lipid metabolism indexes. METHODS: Twenty-six patients with type 2 diabetes mellitus complicated with coronary heart disease were selected to compare the changes of glucose and lipid metabolism indexes and intestinal flora (high-throughput sequencing technique) before and after liraglutide treatment, and to analyze the correlation between glucose and lipid metabolism indexes and intestinal flora. RESULTS: Compared with those before treatment, the indexes of glucose metabolism and lipid metabolism in the patients were significantly decreased (P<0.01). Liraglutide had no significant effect on the diversity of intestinal flora (P>0.05), but can significantly change the composition of intestinal flora (P<0.05). While beneficial bacteria such as Lachnospiraceae increased significantly, it significantly reduced the abundance of pathogenic bacteria such as Escherichia_Shigella (P<0.05), and promoted the production of short-chain fatty acids and body metabolism. CONCLUSION: Lilalutide can affect the composition of intestinal flora in type 2 diabetes patients with coronary heart disease, and then participate in the regulation of glucose and lipid metabolism.

Key words: type 2 diabetes, coronary heart disease, intestinal flora, liraglutide

中图分类号:

R587.1

邢英, 郑嵘炅, 姜春晖, 玛依拉·卡哈尔, 木胡牙提·乌拉斯汉. 利拉鲁肽治疗后2型糖尿病合并冠心病患者肠道菌群变化及其与糖、脂代谢指标相关性[J]. 中国临床药理学与治疗学, 2025, 30(8): 1084-1091.

XING Ying, ZHENG Rongjiong, JIANG Chunhui, Mayila·kahaer, Muhuyati·wulasihan. Changes of intestinal flora in patients with type 2 diabetes mellitus complicated with coronary heart disease after liraglutide treatment and its correlation with glucose and lipid metabolism indexes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1084-1091.

参考文献

[1] Chen J, Yin D, Dou K.Intensified glycemic control by HbA1c for patients with coronary heart disease and Type 2 diabetes: a review of findings and conclusions[J]. Cardiovasc Diabetol, 2023, 22. DOI:10.1186/s12933-023-01875-8.
[2] Luo H, Huemer MT, Petrera A, et al.Association of plasma proteomics with incident coronary heart disease in individuals with and without type 2 diabetes: results from the population-based KORA study[J]. Cardiovasc Diabetol, 2024, 23(1). Doi:10.1186/s12933-024-02143-z.
[3] Cai Y, Li Y, Xiong Y, et al.Diabetic foot exacerbates gut mycobiome dysbiosis in adult patients with type 2 diabetes mellitus: revealing diagnostic markers[J]. Nutr Diabetes, 2024, 14(1): 71.
[4] 邢英. GLP-1通过调节脂代谢基因及肠道菌群改善非酒精性脂肪性肝病的机制研究 [D].乌鲁木齐: 新疆医科大学, 2021.
[5] 邢英, 郑嵘炅, 姜春晖, 等. 二甲双胍与利拉鲁肽对超重2型糖尿病患者肠道菌群的影响[J]. 传染病信息, 2021, 34(1): 56-62.
[6] Ying X, Rongjiong Z, Kahaer M, et al.Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease[J]. Front Microbiol, 2023, 14: 1088187.
[7] Li J, Wang M, Ma S, et al.Association of gastrointestinal microbiome and obesity with gestational diabetes mellitus-an updated globally based review of the high-quality literatures[J]. Nutr Diabetes, 2024, 14(1). DOI:10.1038/s41387-024-00291-5.
[8] Caruso P, Ida Maiorino M, Longo M, et al.Liraglutide for lower limb perfusion in people with type 2 diabetes and peripheral artery disease: the stardust randomized clinical trial[J]. JAMA Network Open, 2024, 7(3): 12. DOI:10.1001/jamanetworkopen.2024.1545.
[9] Wu H, Tremaroli V, Bckhed F.Linking microbiota to human diseases: a systems biology perspective[J]. Trends Endocrinol Metab, 2015, 26(12): 758-770.
[10] 张爱敏, 高宇, 孙启天, 等. 女性2型糖尿病合并冠心病患者肠道菌群特征及相关性分析[J]. 中华内分泌代谢杂志, 2022, 38(2): 100-104.
[11] 彭威风, 张帆, 杨若言, 等. 降糖药对肠道菌群组成和多样性的影响[J]. 中国微生态学杂志, 2022, 34(4): 485-488, 492.
[12] Louis P, Flint HJ.Formation of propionate and butyrate by the human colonic microbiota[J]. Environ Microbiol, 2017, 19(1): 29-41.
[13] Violi F, Cammisotto V, Bartimoccia S, et al.Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease[J]. Nat Rev Cardiol, 2023, 20(1): 24-37.
[14] Zhang B, Wang X, Xia R, et al. Gut microbiota in coronary artery disease: a friend or foe? [J]. Bioscience Rep, 2020, 40(5): BSR20200454.
[15] Nowrouzi-Sohrabi P, Soroush N, Tabrizi R, et al.Effect of liraglutide on cardiometabolic risk profile in people with coronary artery disease with or without type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials[J]. Front Pharmacol, 2021, 12: 618208.
[16] Al Bataineh M, Künstner A, Dash N, et al.Uncovering the relationship between gut microbial dysbiosis, metabolomics, and dietary intake in type 2 diabetes mellitus and in healthy volunteers: a multi-omics analysis[J]. Sci Rep, 2023, 13: 17943.
[17] Kang L, Li P, Wang D, et al.Alterations in intestinal microbiota diversity, composition, and function in patients with sarcopenia[J]. Sci Rep, 2021, 11(1): 4628.
[18] Jiang Z, Zhuo LB, He Y, et al.The gut microbiota-bile acid axis links the positive association between chronic insomnia and cardiometabolic diseases[J]. Nat Commun, 2022, 13(1): 3002.
[19] Zhang J.Microbial stars: shedding light on gut microbes'role in insulin resistance and innovative diabetes therapies[J]. Gut Microbes, 2024, 16(1): 2307581.
[20] Baars D, Fondevila M, Meijnikman A, et al.The central role of the gut microbiota in the pathophysiology and management of type 2 diabetes[J]. Cell Host Microbe, 2024, 32(8): 1280-1300.

利拉鲁肽治疗后2型糖尿病合并冠心病患者肠道菌群变化及其与糖、脂代谢指标相关性

Changes of intestinal flora in patients with type 2 diabetes mellitus complicated with coronary heart disease after liraglutide treatment and its correlation with glucose and lipid metabolism indexes

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张孟丽, 吴芳芳, 谭栀恩, 欧敏, 刘灵杰, 陆纳, 乔丽娅, 杨晓男. 支链氨基酸和芳香族氨基酸对2型糖尿病作用进展[J]. 中国临床药理学与治疗学, 2025, 30(4): 526-532.
[2]	张译冰, 黄钰涵, 郁亚南, 周婷婷, 吴一希, 王晓彤, 王涛. TCF7L2 rs290487基因多态性与艾塞那肽疗效的相关性研究[J]. 中国临床药理学与治疗学, 2025, 30(3): 374-384.
[3]	刘子涵, 杜文雨, 郭彩会, 王智, 李颖, 董占军. 恩格列净治疗2型糖尿病和心肾获益的研究进展[J]. 中国临床药理学与治疗学, 2025, 30(3): 412-418.
[4]	王梦珂, 甘超, 袁玥, 邹婧怡, 王珍, 李淑云, 吕海宏. 2型糖尿病肾脏病与TMAO的相关性研究[J]. 中国临床药理学与治疗学, 2024, 29(6): 661-670.
[5]	彭园园, 陈碧莲. 氧化三甲胺影响冠心病和抗血小板药物疗效的研究进展[J]. 中国临床药理学与治疗学, 2024, 29(5): 590-595.
[6]	王小川, 王汉超, 姚宇, 李丽, 何高燕, 李博, 朱涛. 慢性阻塞性肺疾病急性加重期合并2型糖尿病患者的临床特征和危险因素分析与治疗[J]. 中国临床药理学与治疗学, 2024, 29(4): 392-400.
[7]	白玉, 姚娜, 解小艺, 吴曼迪, 崔应辉, 池永斌, 郭建荣. 丙酮酸钠对2型糖尿病大鼠体外贮存红细胞形态结构和功能的影响[J]. 中国临床药理学与治疗学, 2024, 29(2): 139-145.
[8]	沈纪中, 唐继发. 胰岛素泵短期强化治疗2型糖尿病的疗效及影响因素分析[J]. 中国临床药理学与治疗学, 2024, 29(2): 171-176.
[9]	孙红, 韩超, 雷道赟, 刘金明. 利拉鲁肽通过β-arrestin2/STING/TBK1通路改善老年小鼠术后认知功能障碍[J]. 中国临床药理学与治疗学, 2024, 29(12): 1419-1426.
[10]	李淑云, 邹婧怡, 王珍, 王梦珂, 袁玥, 吕海宏. 维生素D水平与女性2型糖尿病合并尿失禁之间的相关性[J]. 中国临床药理学与治疗学, 2024, 29(12): 1427-1434.
[11]	周鑫, 王智, 杜文雨, 刘子涵, 李颖, 董占军. 2型糖尿病新药及候选药物临床试验研究进展[J]. 中国临床药理学与治疗学, 2024, 29(10): 1185-1193.
[12]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[13]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[14]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[15]	张强, 郑华军, 李权. 基于肠道菌群干预在治疗自闭症谱系障碍中的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(4): 475-480.